EUVIMEDEUVIMED entdecken
Open Access

Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy

Daniel J Farkas iD, Ziva D Cooper iD, Laila N Heydari, Amanda C Hughes, Scott M Rawls, Sara Jane Ward

Cannabis and Cannabinoid Research · 2023

DOI: 10.1089/can.2023.0064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cannabis and Cannabinoid Research, 2023. Verfasst von Daniel J Farkas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Alkaloids, Cannabinoids, Chronic Pain, Mitragyna. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic neuropathic pain is as a severe detriment to overall quality of life for millions of Americans. Current pharmacological treatment options for chronic neuropathic pain are generally limited in efficacy and may pose serious adverse effects such as risk of abuse, nausea, dizziness, and cardiovascular events. Therefore, many individuals have resorted to methods of pharmacological self-treatment. This narrative review summarizes the existing literature on the utilization of two novel approaches for the treatment of chronic pain, cannabinoid constituents of Cannabis sativa and alkaloid constituents of Mitragyna speciosa (kratom), and speculates on the potential therapeutic benefits of co-administration of these two classes of compounds.

Methods

We conducted a narrative review summarizing the primary motivations for use of both kratom and cannabis products based on epidemiological data and summarize the pre-clinical evidence supporting the application of both kratom alkaloids and cannabinoids for the treatment of chronic pain. Data collection was performed using the PubMed electronic database. The following word combinations were used: kratom and cannabis, kratom and pain, cannabis and pain, kratom and chronic pain, and cannabis and chronic pain.

Results

Epidemiological evidence reports that the self-treatment of pain is a primary motivator for use of both kratom and cannabinoid products among adult Americans. Further evidence shows that use of cannabinoid products may precede kratom use, and that a subset of individuals concurrently uses both kratom and cannabinoid products. Despite its growing popularity as a form of self-treatment of pain, there remains an immense gap in knowledge of the therapeutic efficacy of kratom alkaloids for chronic pain in comparison to that of cannabis-based products, with only three pre-clinical studies having been conducted to date.

Conclusion

There is sufficient epidemiological evidence to suggest that both kratom and cannabis products are used to self-treat pain, and that some individuals actively use both drugs, which may produce potential additive or synergistic therapeutic benefits that have not yet been characterized. Given the lack of pre-clinical investigation into the potential therapeutic benefits of kratom alkaloids against forms of chronic pain, further research is warranted to better understand its application as a treatment alternative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlkaloidsCannabinoidsChronic PainMitragynaAnimalsHumansNeuralgiaPlant Extracts

Stichwörter der Autor:innen

cannabinoidscannabischronic painkratommitragyninepain

Substanzen

AlkaloidsCannabinoidsPlant Extracts

Autor:innen und Institutionen

  • Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
  • Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California, USA.
  • UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California, USA.
  • Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, California, USA.
  • Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Daniel J Farkas, Ziva D Cooper

Förderung

  • NIDA NIH HHS

Zitieren

APA

Farkas, D. J., Cooper, Z. D., Heydari, L. N., Hughes, A. C., Rawls, S. M., & Ward, S. J. (2023). Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy. Cannabis and Cannabinoid Research. https://doi.org/10.1089/can.2023.0064

Vancouver

Farkas DJ, Cooper ZD, Heydari LN, Hughes AC, Rawls SM, Ward SJ. Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy. Cannabis and Cannabinoid Research. 2023. doi:10.1089/can.2023.0064

BibTeX
@article{Farkas2023,
  author = {Farkas, Daniel J and Cooper, Ziva D and Heydari, Laila N and Hughes, Amanda C and Rawls, Scott M and Ward, Sara Jane},
  title = {Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy},
  journal = {Cannabis and Cannabinoid Research},
  year = {2023},
  doi = {10.1089/can.2023.0064}
}
Kostenlos starten →